Most Read Articles
03 Apr 2018
Optimal delivery or duration of systemic corticosteroids in atopic dermatitis (AD) cannot be established as there is not enough strong evidence in existing literature, suggests a recent study.
15 Jan 2018
Body surface area (BSA) affected by psoriasis can be measured to target diabetes prevention efforts for patients with psoriasis, a recent study suggests.
Pearl Toh, 5 days ago
Taking the oral extract product of the fern Polypodium leucotomos (PLE) on top of the standard topical hydroquinone cream and sunscreen reduces the severity of melasma to a greater extent compared with the standard treatment alone in Asian patients, a pilot study has shown.
Tristan Manalac, 10 Mar 2018
Cost of treatment is a major driver of patients’ primary nonadherence to acne medication, according to a recent study. Physicians who openly discuss medications costs and provide a plan of action in case patients are unable to fill prescriptions may improve treatment adherence.

CDKN2A mutation status, family history of melanoma tied to worse outcomes in MPM patients

13 Nov 2017

Family history of melanoma and CDKN2A mutation status significantly affect the risks of developing subsequent melanomas and other cancers and survival outcomes in patients with multiple primary melanomas (MPMs), a recent study has shown.

To determine how family history of melanoma and germline CDKN2A mutation status affected outcomes of MPM patients, researchers retrieved comprehensive data on cancer diagnoses and deaths of MPM patients, their first-degree relatives and matched controls from Swedish national healthcare and population registries.

Familial cases of MPM with germline CDKN2A mutations were youngest at the diagnosis of their second melanoma (median age 42 years) and had the highest relative risks (RR) of developing >2 melanomas (RR, 238.4; 95 percent CI, 74.8 to 759.9) among the MPM cohorts compared with controls.

Compared to controls, only those with CDKN2A-mutated MPM cases (RR, 3.6; 1.9 to 147.1) and their first-degree relatives (RR, 3.2; 1.9 to 5.6) had elevated risks of nonskin cancers. Moreover, survival was worse in CDKN2A-mutated MPM cases compared with both cases with familial (hazard ratio [HR], 3.0; 1.3 to 8.1) and sporadic wild-type MPM (HR, 2.63; 1.3 to 5.4).

“Our study examined outcomes in subgroups of MPM patients, which affected the sample size of the study groups,” researchers noted.

In a separate study, the same researchers concluded that CDKN2A-mutated cases had significantly worse survival than nonskin cancers and from melanoma compared with melanoma cases without CDKN2A mutations. [J Natl Cancer Inst 2016;doi:10.1093/jnci/djw135]

“Further studies are required to elucidate possible mechanisms behind increased carcinogen susceptibility and the more aggressive melanoma phenotype in CDKN2A mutation carriers,” they added.

Editor's Recommendations
Most Read Articles
03 Apr 2018
Optimal delivery or duration of systemic corticosteroids in atopic dermatitis (AD) cannot be established as there is not enough strong evidence in existing literature, suggests a recent study.
15 Jan 2018
Body surface area (BSA) affected by psoriasis can be measured to target diabetes prevention efforts for patients with psoriasis, a recent study suggests.
Pearl Toh, 5 days ago
Taking the oral extract product of the fern Polypodium leucotomos (PLE) on top of the standard topical hydroquinone cream and sunscreen reduces the severity of melasma to a greater extent compared with the standard treatment alone in Asian patients, a pilot study has shown.
Tristan Manalac, 10 Mar 2018
Cost of treatment is a major driver of patients’ primary nonadherence to acne medication, according to a recent study. Physicians who openly discuss medications costs and provide a plan of action in case patients are unable to fill prescriptions may improve treatment adherence.